Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review

References

• Hanto D W, Frizzera G, Gajl-Peczalska J, Purtilo D T, Klein G, Simmons R L, et al. The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma. Transplant Proc 1981; 13: 756–760
   PubMed Web of Science ®Google Scholar
• Penn I, Hammond W, Brettschneider L, Starzl T E. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106–112
   PubMed Web of Science ®Google Scholar
• Swerdlow S H. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997; 14: 2–7
   PubMed Web of Science ®Google Scholar
• Swerdlow A J, Higgins C D, Hunt B J, Thomas J A, Burke M M, Crawford D H, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation. A cohort study of the relation to Epstein-Barr virus. Transplantation 2000; 69: 897–904
   PubMed Web of Science ®Google Scholar
• Wilkinson A H, Smith J L, Hunsicker L G, Tobacman J, Kapelanski D P, Johnson M, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47: 293–296
   PubMed Web of Science ®Google Scholar
• Starzl T E, Nalesnik M A, Porter K A, Ho M, Iwatsuki S, Griffith B P, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587
   PubMed Web of Science ®Google Scholar
• Pinkerton C R, Hann I, Weston C L, Mapp T, Wotherspoon A, Hobson R, et al. Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol 2002; 118: 456–461
   PubMed Web of Science ®Google Scholar
• Berinstein N L, Grillo-Lopez A J, White C A, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995–1001
   PubMed Web of Science ®Google Scholar
• Nguyen D T, Amess J A, Doughty H, Hendry L, Diamond L W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76–82
   PubMed Web of Science ®Google Scholar
• Anderson K C, Bates M P, Slaughenhoupt B L, Pinkus G S, Schlossman S F, Nadler L M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424–1433
   PubMed Web of Science ®Google Scholar
• Maloney D G. Mechanism of action of rituximab. Anticancer Drugs 2001; 12(Suppl 2)S1–S4
   PubMed Web of Science ®Google Scholar
• Ifthikharuddin J J, Mieles L A, Rosenblatt J D, Ryan C K, Sahasrabudhe D M. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol 2000; 65: 171–173
   PubMed Web of Science ®Google Scholar
• Reff M E, Carner K, Chambers K S, Chinn P C, Leonard J E, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445
   PubMed Web of Science ®Google Scholar
• Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29(Suppl 2)2–9
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001; 7: 709–723
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Burris H A, III, Scullin D C, Jr, Corso S W, Yardley D A, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261–4267
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Vose J M, Link B K, Grossbard M L, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397
   PubMed Web of Science ®Google Scholar
• Milpied N, Vasseur B, Parquet N, Garnier J L, Antoine C, Quartier P, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11(Suppl 1)113–116
   PubMed Web of Science ®Google Scholar
• Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa A M, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053–3057
   PubMed Web of Science ®Google Scholar
• Ghobrial I M, Habermann T M, Ristow K M, Ansell S M, Macon W, Geyer S M, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46: 191–196
   PubMed Web of Science ®Google Scholar
• Faye A, Quartier P, Reguerre Y, Lutz P, Carret A S, Dehee A, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112–118
   PubMed Web of Science ®Google Scholar
• Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 2003; 102: 1557–1558
   PubMed Web of Science ®Google Scholar
• Dereure O, Navarro R, Rossi J F, Guilhou J J. Rituximab-induced vasculitis. Dermatology 2001; 203: 83–84
   PubMed Web of Science ®Google Scholar
• Westhoff T H, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer J H, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930
   PubMed Web of Science ®Google Scholar
• Orjuela M, Gross T G, Cheung Y K, Alobeid B, Morris E, Cairo M S. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9: 3945S–3952S
   PubMed Web of Science ®Google Scholar
• Haque T, Taylor C, Wilkie G M, Murad P, Amlot P L, Beath S, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399–1402
   PubMed Web of Science ®Google Scholar